Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
Featured trial
(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

  • 178 views
  • 08 Nov, 2020
  • 1 location
None
Effects of Anakinra in Subjects With Autoimmune Inner Ear Disease

A Phase II randomized, placebo controlled study design of anakinra (Kineret) in corticosteroid-resistant Meniere's disease (CR-MD)and corticosteroid-resistant autoimmune inner ear disease (CR

  • 4 views
  • 15 Sep, 2021
  • 1 location
None
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

cholesterol, have also been shown to decrease inflammation in general as well as at the level of the vessel wall. Anakinra, a therapy that blocks the high levels of interleukin 1 (IL1) that leads to

  • 0 views
  • 17 Feb, 2021
  • 1 location
None
Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome

with Schnitzler's syndrome (SchS) currently well controlled by anakinra therapy. At least 5 but no more than 10 subjects will be enrolled.

  • 1 views
  • 16 Jul, 2021
  • 1 location
None
The Efficacy and Safety of ITF2357 in AIS

reported during treatment with simvastatin, etanercept or anakinra in some but not all patients. ITF2357 is an orally active histon deacetylase inhibitor with a potent anti-inflammatory effect

  • 5 views
  • 07 Nov, 2020
  • 1 location
None
Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis

therapeutic agent for cardiac sarcoidosis. In the current study, researchers aim to evaluate the safety and efficacy of IL-1 blockade with anakinra (IL-1 receptor antagonist) in patients with cardiac

  • 7 views
  • 16 Nov, 2021
  • 2 locations
None
Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis

(RCTs) have explored the efficacy and safety of combining tumour necrosis factor (TNF) inhibitor with another biologic (anakinra, abatacept, rituximab or bimekizumab). Baricitinib is a selective

tofacitinib
antirheumatics
anakinra
prednisone
adalimumab
  • 0 views
  • 21 Jul, 2021
  • 20 locations
None
Woodsmoke Particulate + Prednisone

Deployment of military personnel has been associated with increased respiratory illness likely due, in part, to inhalation of unusual particulate matter (PM), such as from burn pits. Inflammation is a key initial response to inhaled particulates. The researchers have developed a protocol using inhaled wood smoke particles (WSP) as a …

  • 0 views
  • 12 Sep, 2021
  • 1 location
None
Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.

Colchicine acts upstream in the cytokines cascade by inhibiting the NLRP3 inflammasome while IL-6 receptor antagonists (tocilizumab) block the end result of the cytokines cascade. Hence, adding colchicine to tocilizumab with the aim of blocking the early and end products of the cytokines cascade, might reduce the risk of developing …

  • 0 views
  • 20 Nov, 2021
  • 1 location
None
suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)

will be detected using the suPAR biomarker. They will begin early treatment with anakinra in the effort to prevent progression in serious respiratory failure.

respiratory failure
anakinra
covid-19
respiratory tract infection
sulfamethoxazole
  • 22 views
  • 21 Feb, 2021
  • 27 locations